Clinical Trial Update: Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) [Phase 3]

View source ↗

Summary

This entry covers the Phase 3 REVERSE trial of GS010 for vision loss in Leber hereditary optic neuropathy due to the ND4 mutation. Results were posted on Januar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• GS010 (lenadogene nolparvovec)

Snippet

Sponsor: GenSight Biologics | Conditions: Optic, Atrophy, Hereditary, Leber | Phase 3 | Status: COMPLETED | Results posted: 2020-01-23